These findings suggest that therapeutic targeting of mTOR activity by its inhibitors, e.g., RAPA, could be a good strategy to combat the metastatic ccRCC with wild-type PTEN and LTF downregulation (Figure 6F). This evidence concerns the gene PTEN and nonpapillary renal cell carcinoma.